FARMINGDALE, N.Y., Oct. 12 /PRNewswire/ — Misonix, Inc.
(Nasdaq:
MSON), a developer of state of the art, ultrasonic medical
device technology, which worldwide is used for acute health
conditions, has announced a definitive agreement to end its
non-exclusive distribution arrangement in the United States with
Aesculap, Inc. for the SonaStar® Surgical Aspiration System.
As a result, Misonix will assume exclusive responsibility for
the marketing, sales, distribution and service of the SonaStar
effective October 18, 2010, utilizing its previously established 75
person sales and service organization, which began direct to
hospital marketing of the SonaStar late last year.
The SonaStar is used by Neuro and General Surgeons for quick and
efficient removal of both hard and soft tumors while sparing most
vessels. In addition, OsteoSculpt™ bone sculpting
technology can be employed with the SonaStar to safely remove
osseous structures, thus providing access to the surgical site.
“We are very excited about bringing all domestic sales of
SonaStar under our focused sales organization,” said Michael A.
McManus, Jr., President and Chief Executive Officer of Misonix.
“Over time, we expect to gain significant margin improvement and
sales growth by enabling our proprietary sales organization to sell
another one of our key products exclusively under the Misonix
label.”
About Misonix:Misonix, Inc. designs, develops, manufactures
and markets therapeutic ultrasonic medical devices and laboratory
equipment. Misonix’s therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing
a combined market estimated to be in excess of $3 billion annually;
Misonix’s proprietary ultrasonic medical devices are used for wound
debridement, cosmetic surgery, neurosurgery, laparoscopic surgery,
and other surgical and me
‘/>”/>
SOURCE
